Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Groot, J.W.B. de"'
Autor:
Versteijne, E., Dam, J.L. van, Suker, M., Janssen, Q.P., Groothuis, K., Akkermans-Vogelaar, J.M., Besselink, M.G., Bonsing, B.A., Buijsen, J., Busch, O.R., Creemers, G.J.M., Dam, R.M. van, Eskens, F.A.L.M., Festen, S., Groot, J.W.B. de, Koerkamp, B.G., Hingh, I.H. de, Homs, M.Y.V., Hooft, J.E. van, Kerver, E.D., Luelmo, S.A.C., Neelis, K.J., Nuyttens, J., Paardekooper, G.M.R.M., Patijn, G.A., Sangen, M.J.C. van der, Vos-Geelen, J. de, Wilmink, J.W., Zwinderman, A.H., Punt, C.J., Tienhoven, G. van, Eijck, C.H.J. van, Dutch Pancreatic Canc Grp
Publikováno v:
Journal of Clinical Oncology, 40(11), 1220-1230. American Society of Clinical Oncology
Versteijne, E, van Dam, J L, Suker, M, Janssen, Q P, Groothuis, K, Akkermans-Vogelaar, J M, Besselink, M G, Bonsing, B A, Buijsen, J, Busch, O R, Creemers, G-J M, van Dam, R M, Eskens, F A L M, Festen, S, de Groot, J W B, Groot Koerkamp, B, de Hingh, I H, Homs, M Y V, van Hooft, J E, Kerver, E D, Luelmo, S A C, Neelis, K J, Nuyttens, J, Paardekooper, G M R M, Patijn, G A, van der Sangen, M J C, de Vos-Geelen, J, Wilmink, J W, Zwinderman, A H, Punt, C J, van Tienhoven, G & van Eijck, C H J 2022, ' Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer : Long-Term Results of the Dutch Randomized PREOPANC Trial ', Journal of Clinical Oncology, vol. 40, no. 11, pp. 1220-1230 . https://doi.org/10.1200/JCO.21.02233
Journal of Clinical Oncology, 40(11), 1220-+. LIPPINCOTT WILLIAMS & WILKINS
Journal of clinical oncology, 40(11), 1220-1230. American Society of Clinical Oncology
Versteijne, E, van Dam, J L, Suker, M, Janssen, Q P, Groothuis, K, Akkermans-Vogelaar, J M, Besselink, M G, Bonsing, B A, Buijsen, J, Busch, O R, Creemers, G-J M, van Dam, R M, Eskens, F A L M, Festen, S, de Groot, J W B, Groot Koerkamp, B, de Hingh, I H, Homs, M Y V, van Hooft, J E, Kerver, E D, Luelmo, S A C, Neelis, K J, Nuyttens, J, Paardekooper, G M R M, Patijn, G A, van der Sangen, M J C, de Vos-Geelen, J, Wilmink, J W, Zwinderman, A H, Punt, C J, van Tienhoven, G & van Eijck, C H J 2022, ' Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer : Long-Term Results of the Dutch Randomized PREOPANC Trial ', Journal of Clinical Oncology, vol. 40, no. 11, pp. 1220-1230 . https://doi.org/10.1200/JCO.21.02233
Journal of Clinical Oncology, 40(11), 1220-+. LIPPINCOTT WILLIAMS & WILKINS
Journal of clinical oncology, 40(11), 1220-1230. American Society of Clinical Oncology
PURPOSE The benefit of neoadjuvant chemoradiotherapy in resectable and borderline resectable pancreatic cancer remains controversial. Initial results of the PREOPANC trial failed to demonstrate a statistically significant overall survival (OS) benefi
Autor:
Versteijne, E., Suker, M., Groothuis, K., Akkermans-Vogelaar, J.M., Besselink, M.G., Bonsing, B.A., Buijsen, J., Busch, O.R., Creemers, G.J.M., Dam, R.M. van, Eskens, F.A.L.M., Festen, S., Groot, J.W.B. de, Koerkamp, B.G., Hingh, I.H. de, Homs, M.Y.V., Hooft, J.E. van, Kerver, E.D., Luelmo, S.A.C., Neelis, K.J., Nuyttens, J., Paardekooper, G.M.R.M., Patijn, G.A., Sangen, M.J.C. van der, Vos-Geelen, J. de, Wilmink, J.W., Zwinderman, A.H., Punt, C.J., Eijck, C.H. van, Tienhoven, G. van, Dutch Pancreatic Canc Grp
Publikováno v:
Journal of Clinical Oncology, 38(16), 1763-1773. AMER SOC CLINICAL ONCOLOGY
Journal of clinical oncology, 38(16), 1763-1773. American Society of Clinical Oncology
Journal of Clinical Oncology, 38(16), 1763-1773. American Society of Clinical Oncology
J Clin Oncol
Journal of clinical oncology, 38(16), 1763-1773. American Society of Clinical Oncology
Journal of Clinical Oncology, 38(16), 1763-1773. American Society of Clinical Oncology
J Clin Oncol
PURPOSE Preoperative chemoradiotherapy may improve the radical resection rate for resectable or borderline resectable pancreatic cancer, but the overall benefit is unproven. PATIENTS AND METHODS In this randomized phase III trial in 16 centers, patie
Autor:
Mackay, T.M., Smits, F.J., Roos, D., Bonsing, B.A., Bosscha, K., Busch, O.R., Creemers, G.J., Dam, R.M. van, Eijck, C.H.J. van, Gerhards, M.F., Groot, J.W.B. de, Koerkamp, B.G., Mohammad, N.H., Harst, E. van der, Hingh, I.H.J.T. de, Homs, M.Y.V., Kazemier, G., Liem, M.S.L., Meijer, V.E. de, Molenaar, I.Q., Nieuwenhuijs, V.B., Santvoort, H.C. van, Schelling, G.P. van der, Stommel, M.W.J., Tije, A.J. ten, Vos-Geelen, J. de, Wit, F., Wilmink, J.W., Laarhoven, H.W.M. van, Besselink, M.G., Dutch Pancreatic Canc Grp
Publikováno v:
HPB: The official journal of the International Hepato Pancreato Biliary Association, 22(2), 233-240. John Wiley and Sons Inc.
Hpb, 22, 2, pp. 233-240
International Hepato-Pancreato Biliary Association., 22(2), 233. John Wiley and Sons Inc.
HPB, 22(2), 233-240. ELSEVIER SCI LTD
HPB, 22(2), 233-240. John Wiley and Sons Inc.
HPB, 22(2), 233-240. John Wiley & Sons Inc.
Hpb, 22(2), 233-240. ELSEVIER SCI LTD
Mackay, T M, Smits, F J, Roos, D, Bonsing, B A, Bosscha, K, Busch, O R, Creemers, G-J, van Dam, R M, van Eijck, C H J, Gerhards, M F, de Groot, J W B, Groot Koerkamp, B, Haj Mohammad, N, van der Harst, E, de Hingh, I H J T, Homs, M Y V, Kazemier, G, Liem, M S L, de Meijer, V E, Molenaar, I Q, Nieuwenhuijs, V B, van Santvoort, H C, van der Schelling, G P, Stommel, M W J, ten Tije, A J, de Vos-Geelen, J, Wit, F, Wilmink, J W, van Laarhoven, H W M, Besselink, M G & Dutch Pancreatic Cancer Group 2020, ' The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis ', HPB, vol. 22, no. 2, pp. 233-240 . https://doi.org/10.1016/j.hpb.2019.06.019
Hpb, 22, 233-240
Hpb, 22, 2, pp. 233-240
International Hepato-Pancreato Biliary Association., 22(2), 233. John Wiley and Sons Inc.
HPB, 22(2), 233-240. ELSEVIER SCI LTD
HPB, 22(2), 233-240. John Wiley and Sons Inc.
HPB, 22(2), 233-240. John Wiley & Sons Inc.
Hpb, 22(2), 233-240. ELSEVIER SCI LTD
Mackay, T M, Smits, F J, Roos, D, Bonsing, B A, Bosscha, K, Busch, O R, Creemers, G-J, van Dam, R M, van Eijck, C H J, Gerhards, M F, de Groot, J W B, Groot Koerkamp, B, Haj Mohammad, N, van der Harst, E, de Hingh, I H J T, Homs, M Y V, Kazemier, G, Liem, M S L, de Meijer, V E, Molenaar, I Q, Nieuwenhuijs, V B, van Santvoort, H C, van der Schelling, G P, Stommel, M W J, ten Tije, A J, de Vos-Geelen, J, Wit, F, Wilmink, J W, van Laarhoven, H W M, Besselink, M G & Dutch Pancreatic Cancer Group 2020, ' The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis ', HPB, vol. 22, no. 2, pp. 233-240 . https://doi.org/10.1016/j.hpb.2019.06.019
Hpb, 22, 233-240
Contains fulltext : 226028.pdf (Publisher’s version ) (Closed access) BACKGROUND: The relation between type of postoperative complication and not receiving chemotherapy after resection of pancreatic ductal adenocarcinoma (PDAC) is unclear. The aim
Autor:
Blankenstein, S.A., Bonenkamp, J.J., Aarts, M.J.B., Berkmortel, F.W.P.J. van den, Blank, C.U., Blokx, W.A.M., Boers-Sonderen, M.J., Eertwegh, A.J.M. van den, Franken, M.G., Groot, J.W.B. de, Haanen, J.B.A.G., Hospers, G.A.P., Kapiteijn, E.W., Not, O.J. van, Piersma, D., Rijn, R.S. van, Suijkerbuijk, K.P.M., Veldt, A.A.M. van der, Vreugdenhil, G., Westgeest, H.M., Wouters, M.W.J.M., Akkooi, A.C.J. van
Publikováno v:
Blankenstein, S A, Bonenkamp, J J, Aarts, M J B, van den Berkmortel, F W P J, Blank, C U, Blokx, W A M, Boers-Sonderen, M J, van den Eertwegh, A J M, Franken, M G, de Groot, J W B, Haanen, J B A G, Hospers, G A P, Kapiteijn, E W, van Not, O J, Piersma, D, van Rijn, R S, Suijkerbuijk, K P M, van der Veldt, A A M, Vreugdenhil, G, Westgeest, H M, Wouters, M W J M & van Akkooi, A C J 2023, ' Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease? ', Annals of Surgical Oncology, vol. 30, no. 1, pp. 573-586 . https://doi.org/10.1245/s10434-022-12600-2
Annals of Surgical Oncology, 30(1), 573-586. Springer New York
Annals of Surgical Oncology, 30, 1, pp. 573-586
Annals of Surgical Oncology, 30, 573-586. SPRINGER
Annals of Surgical Oncology, 30(1), 573-586. Springer, Cham
Annals of Surgical Oncology, 30, 573-586
Annals of Surgical Oncology. SPRINGER
Annals of Surgical Oncology, 30(1), 573-586. Springer New York
Annals of Surgical Oncology, 30, 1, pp. 573-586
Annals of Surgical Oncology, 30, 573-586. SPRINGER
Annals of Surgical Oncology, 30(1), 573-586. Springer, Cham
Annals of Surgical Oncology, 30, 573-586
Annals of Surgical Oncology. SPRINGER
Item does not contain fulltext INTRODUCTION: Sentinel lymph node biopsy (SLNB) is important for staging in patients with primary cutaneous melanoma. Did having previously undergone SLNB also affect outcomes in patients once they have progressed to me
Autor:
Boekhout, A.H., Rogiers, A., Jozwiak, K., Boers-Sonderen, M.J., Eertwegh, A.J. van den, Hospers, G.A., Groot, J.W.B. de, Aarts, M.J.B., Kapiteijn, E., Tije, A.J. ten, Piersma, D., Vreugdenhil, G., Veldt, A.A. van der, Suijkerbuijk, K.P.M., Rozeman, E.A., Neyns, B., Janssen, K.J., Poll-franse, L.V. van de, Blank, C.U.
Background: Checkpoint inhibitors have changed overall survival for patients with advanced melanoma. However, there is a lack of data on health-related quality of life (HRQoL) of long-term advanced melanoma survivors, years after treatment. Therefore
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_____10693::b46188c36dd191dd0d4ca7767d656e54
https://hdl.handle.net/1887/3195919
https://hdl.handle.net/1887/3195919
Autor:
Dekker, N., Wanten, G.J.A., Bleumink, M., Groot, J.W.B. de, Wijkerslooth, L.R. de, Netters, F.J.S.
Publikováno v:
Nederlands Tijdschrift voor Geneeskunde, 164
Item does not contain fulltext Total parenteral nutrition may be considered for a carefully selected group of palliative patients with ileus. Predictive factors include a strong desire to live, low burden of disease other than the ileus and expected
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::6da5b07eff6adfc718927c8d2ad4f16d
http://hdl.handle.net/2066/224851
http://hdl.handle.net/2066/224851
Autor:
Braak, R.R.J.C. van den, Rijssen, L.B. van, Kleef, J.J. van, Vink, G.R., Berbee, M., Henegouwen, M.I.V., Bloemendal, H.J., Bruno, M.J., Burgmans, M.C., Busch, O.R.C., Coene, P.P.L.O., Coupe, V.M.H., Dekker, J.W.T., Eijck, C.H.J. van, Elferink, M.A.G., Erdkamp, F.L.G., Grevenstein, W.M.U. van, Groot, J.W.B. de, Grieken, N.C.T. van, Hingh, I.H.J.T. de, Hulshof, M.C.C.M., Ijzermans, J.N.M., Kwakkenbos, L., Lemmens, V.E.P.P., M. los, Meijer, G.A., Molenaar, I.Q., Nieuwenhuijzen, G.A.P., Noo, M.E. de, Poll-Franse, L.V. van de, Punt, C.J.A., Rietbroek, R.C., Roeloffzen, W.W.H., Rozema, T., Ruurda, J.P., Sandick, J.W. van, Schiphorst, A.H.W., Schipper, H., Siersema, P.D., Slingerland, M., Sommeijer, D.W., Spaander, M.C.W., Sprangers, M.A.G., Stockmann, H.B.A.C., Strijker, M., Tienhoven, G. van, Timmermans, L.M., Tjin-a-Ton, M.L.R., Velden, A.M.T. van der, Verhaar, M.J., Verkooijen, H.M., Vles, W.J., Vos-Geelen, J.M.P.G.M. de, Wilmink, J.W., Zimmerman, D.D.E., Oijen, M.G.H. van, Koopman, M., Besselink, M.G.H., Laarhoven, H.W.M. van, Dutch Pancreatic Canc Grp, Dutch Upper GI Canc Grp, PLCRC Working Grp
Publikováno v:
Acta Oncologica, 57(2), 195-202. Routledge/Taylor & Francis Group
Acta Oncologica, 57(2), 195-202. Informa Healthcare
Acta Oncologica, 57, 2, pp. 195-202
Coebergh van den Braak, R R J, van Rijssen, L B, van Kleef, J J, Vink, G R, Berbee, M, van Berge Henegouwen, M I, Bloemendal, H J, Bruno, M J, Burgmans, M C, Busch, O R C, Coene, P P L O, Coupé, V M H, Dekker, J W T, van Eijck, C H J, Elferink, M A G, Erdkamp, F L G, van Grevenstein, W M U, de Groot, J W B, van Grieken, N C T, de Hingh, I H J T, Hulshof, M C C M, Ijzermans, J N M, Kwakkenbos, L, Lemmens, V E P P, Los, M, Meijer, G A, Molenaar, I Q, Nieuwenhuijzen, G A P, de Noo, M E, van de Poll-Franse, L V, Punt, C J A, Rietbroek, R C, Roeloffzen, W W H, Rozema, T, Ruurda, J P, van Sandick, J W, Schiphorst, A H W, Schipper, H, Siersema, P D, Slingerland, M, Sommeijer, D W, Spaander, M C W, Sprangers, M A G, Stockmann, H B A C, Strijker, M, van Tienhoven, G, Timmermans, L M, Tjin-a-Ton, M L R, van der Velden, A M T, Verhaar, M J, Verkooijen, H M, Vles, W J, de Vos-Geelen, J M P G M, Wilmink, J W, Zimmerman, D D E, van Oijen, M G H, Koopman, M, Besselink, M G H & van Laarhoven, H W M 2018, ' Nationwide comprehensive gastro-intestinal cancer cohorts : the 3P initiative ', Acta Oncologica, vol. 57, no. 2, pp. 195-202 . https://doi.org/10.1080/0284186X.2017.1346381
Acta oncologica (Stockholm, Sweden), 57(2), 195-202. Informa Healthcare
Acta Oncologica, 57(2), 195. Informa Healthcare
Acta Oncologica, 57(2), 195-202
Acta Oncologica, 57, 195-202
Acta Oncologica, 57(2), 195-202. TAYLOR & FRANCIS LTD
Acta Oncologica, 57(2), 195-202. Informa Healthcare
Acta Oncologica, 57, 2, pp. 195-202
Coebergh van den Braak, R R J, van Rijssen, L B, van Kleef, J J, Vink, G R, Berbee, M, van Berge Henegouwen, M I, Bloemendal, H J, Bruno, M J, Burgmans, M C, Busch, O R C, Coene, P P L O, Coupé, V M H, Dekker, J W T, van Eijck, C H J, Elferink, M A G, Erdkamp, F L G, van Grevenstein, W M U, de Groot, J W B, van Grieken, N C T, de Hingh, I H J T, Hulshof, M C C M, Ijzermans, J N M, Kwakkenbos, L, Lemmens, V E P P, Los, M, Meijer, G A, Molenaar, I Q, Nieuwenhuijzen, G A P, de Noo, M E, van de Poll-Franse, L V, Punt, C J A, Rietbroek, R C, Roeloffzen, W W H, Rozema, T, Ruurda, J P, van Sandick, J W, Schiphorst, A H W, Schipper, H, Siersema, P D, Slingerland, M, Sommeijer, D W, Spaander, M C W, Sprangers, M A G, Stockmann, H B A C, Strijker, M, van Tienhoven, G, Timmermans, L M, Tjin-a-Ton, M L R, van der Velden, A M T, Verhaar, M J, Verkooijen, H M, Vles, W J, de Vos-Geelen, J M P G M, Wilmink, J W, Zimmerman, D D E, van Oijen, M G H, Koopman, M, Besselink, M G H & van Laarhoven, H W M 2018, ' Nationwide comprehensive gastro-intestinal cancer cohorts : the 3P initiative ', Acta Oncologica, vol. 57, no. 2, pp. 195-202 . https://doi.org/10.1080/0284186X.2017.1346381
Acta oncologica (Stockholm, Sweden), 57(2), 195-202. Informa Healthcare
Acta Oncologica, 57(2), 195. Informa Healthcare
Acta Oncologica, 57(2), 195-202
Acta Oncologica, 57, 195-202
Acta Oncologica, 57(2), 195-202. TAYLOR & FRANCIS LTD
Contains fulltext : 190038.pdf (Publisher’s version ) (Open Access) Background: The increasing sub-classification of cancer patients due to more detailed molecular classification of tumors, and limitations of current trial designs, require innovati
Autor:
Boer, F.J. de, Stigt, J.A., Netters, F.J.S., Koornstra, R.H., Tije, A.J. Ten, Groot, J.W.B. de
Publikováno v:
Nederlands Tijdschrift voor Geneeskunde, 163
Item does not contain fulltext Immune therapy is increasingly used as an effective treatment for various types of cancer. The response of tumours to immune therapy is different from conventional chemotherapy. In about 10% of patients, pseudoprogressi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::253c34c5bc8477c9e18a8e4b85365f17
https://hdl.handle.net/2066/208955
https://hdl.handle.net/2066/208955
Publikováno v:
Nederlands Tijdschrift voor Geneeskunde, 163
Item does not contain fulltext Immunotherapy induces a response against cancer by activating the immune system. Examples are therapies with checkpoint inhibitors, oncolytic viruses and chimeric antigen receptor T-cells (CAR T-cells). These therapies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::c2ee9407665af3abe930ee66e393ad74
https://hdl.handle.net/2066/205379
https://hdl.handle.net/2066/205379
Autor:
Zeijl, M.C.T. van, Eertwegh, A.J. van den, Wouters, M., Jochems, A., Schouwenburg, M.G., Haanen, J., Aarts, M.J., Berkmortel, F. van den, Groot, J.W.B. de, Hospers, G.A., Kapiteijn, E., Koornstra, R.H., Piersma, D., Rijn, R.S. van, Suijkerbuijk, K.P., Tije, A.J. Ten, Veldt, A.A.M. van der, Vreugdenhil, G., Hoeven, K.J.M. van der
Publikováno v:
Nederlands Tijdschrift voor Geneeskunde, 162, D2420
Nederlands Tijdschrift voor Geneeskunde, 162, pp. D2420
Nederlands Tijdschrift voor Geneeskunde, 162, pp. D2420
Item does not contain fulltext OBJECTIVE: To evaluate treatment strategies and survival of patients with unresectable stage IIIc or IV melanoma since the 2012 introduction of new drugs in the Netherlands. DESIGN: Prospective cohort study. METHOD: We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::38549d9d897d18ee0fb4014fc013ccda
http://hdl.handle.net/2066/196570
http://hdl.handle.net/2066/196570